BridgeMD
Tests treatment safety and results for Osteoporosis
Official title Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis
ClinicalTrials.gov ID: NCT07242612
What this study is testing
What is Alendronate, Ibandronate; Risedronate?
Alendronate, Ibandronate; Risedronate is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for osteoporosis.
Also referred to as Fosamax; Bonviva; Actonel.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study investigates the use of blood tests known as Bone Turnover Markers (BTMs) to quickly monitor the effectiveness of osteoporosis treatment in postmenopausal women. Osteoporosis, which weakens bones and increases fracture risk, is typically monitored using a DEXA scan to measure bone density (BMD), but this method changes slowly.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 50 and older
You may be able to join if
- Postmenopausal women (at least one year since last menstrual cycle).
- Age greater than 50 years.
- Diagnosis of primary osteoporosis.
- Currently not on any anti-osteoporosis medications.
- Not taking Calcium or Vitamin D supplements.
You likely can't join if
- Women with multiple vertebral fractures or severe lumbar degenerative changes.
- Use of hormone/estrogen therapy, calcitonin, oral bisphosphonates, IV ibandronate, IV Zoledronic acid, denosumab, or teriparatide within the past 18...
- Use of corticosteroids (short or long-term).
- History of hyperthyroidism, hypothyroidism, liver disease, kidney disease, or tumors.
- Presence of secondary causes of osteoporosis (e.g., eating disorders, celiac disease, diabetes, hematologic disorders).
See the full eligibility criteria
- Postmenopausal women (at least one year since last menstrual cycle).
- Age greater than 50 years.
- Diagnosis of primary osteoporosis.
- Currently not on any anti-osteoporosis medications.
- Not taking Calcium or Vitamin D supplements.
- Volunteer to participate and provide informed consent.
- Women with multiple vertebral fractures or severe lumbar degenerative changes.
- Use of hormone/estrogen therapy, calcitonin, oral bisphosphonates, IV ibandronate, IV Zoledronic acid, denosumab, or teriparatide within the past 18 months.
- Use of corticosteroids (short or long-term).
- History of hyperthyroidism, hypothyroidism, liver disease, kidney disease, or tumors.
- Presence of secondary causes of osteoporosis (e.g., eating disorders, celiac disease, diabetes, hematologic disorders).
The study team makes the final eligibility decision.
Where it's taking place
- Peshawar, Khyber Pakhtunkhwa, Pakistan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 50 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Peshawar, Khyber Pakhtunkhwa, Pakistan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.